



Final major market patent granted for Xanamem™

- Canadian authorities grant key patent for Xanamem
- Key Xanamem patents now granted across all major markets, including US, UK, EU, Japan, China, Canada, Australia
- These countries represent over 80% of the global Alzheimer's market
- Patents cover Xanamem for use across a broad range of neurological and metabolic diseases, including Alzheimer's disease
- Patents extend out to at least 2031

Sydney, 11 October 2017: Actinogen Medical (ASX: ACW) is pleased to advise that the Canadian Intellectual Property Office has granted a further key patent for Xanamem. This Canadian patent represents the final major market patent to be granted for Xanamem.

Key patents for Xanamem have now been granted in all major markets, including the USA, UK, EU, Japan, China, Canada and Australia. These patents extend out to at least 2031.

The patents cover the composition-of-matter of Xanamem and its use in an extensive array of neurological and metabolic diseases, including Alzheimer's disease. Patents for pharmaceutical compounds and compositions are the key patents sought by the pharmaceutical and biotech industries, and provide exclusive rights to the use of that class of drugs.

"The strength of the Xanamem IP we are developing is reaffirmed with the grant of patents in these key countries. Xanamem is now patent protected in more than 80% of the global Alzheimer's market, signalling the significant value of the Xanamem IP that we hope to commercialise in the future." said Dr Bill Ketelbey, CEO of Actinogen Medical.

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer's disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn, and is set to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. This enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer's disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer's disease.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu, will enrol 174 patients at 20 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.